Skip to main content

Edwards Lifesciences Corp ratios

  • EW · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$107.15+1.28%Close 13 Nov 2026 · Market value $61.51B

In fiscal 2025 (the year to 31 Dec 2025), Edwards Lifesciences Corp had an operating margin of 20.8%, a return on equity of 10.6%, a return on invested capital of 13.7%.

From Edwards Lifesciences Corp's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025.

Annual

Edwards Lifesciences Corp ratios, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Gross margin66.1%69.8%71.8%70.8%74.2%74.7%73.1%75.2%73.1%74.5%74.8%74.4%75.4%76.1%83.8%80.5%79.5%78.0%
Operating margin13.9%22.8%18.7%16.9%20.4%25.2%49.7%25.6%25.3%31.7%20.1%26.4%20.5%32.3%33.6%26.1%25.3%20.8%
Net margin10.4%17.3%15.1%14.1%15.3%19.0%34.9%19.8%19.2%17.0%19.4%24.1%18.8%28.7%34.1%28.0%76.7%17.7%
Free cash flow margin8.3%7.7%13.1%13.8%13.3%17.8%40.4%17.9%17.8%24.2%18.5%21.4%14.8%26.9%21.8%12.8%5.3%22.0%
Return on equity14.7%22.5%17.7%17.9%20.7%25.7%43.4%21.1%22.2%20.9%23.7%28.7%18.9%28.9%26.1%22.5%50.2%10.6%
Return on assets—14.0%13.0%12.6%13.9%15.9%26.3%13.4%13.5%12.1%12.9%17.4%11.7%19.0%15.5%13.2%11.1%7.8%
Return on capital employed—22.7%19.6%18.4%22.0%24.4%42.3%19.2%19.9%26.5%17.2%22.9%15.0%24.5%20.3%17.0%14.0%10.8%
Return on invested capital—22.8%21.7%21.2%22.9%28.3%53.1%25.3%22.9%19.1%19.7%27.1%17.8%27.1%21.6%18.4%17.6%13.7%
Current ratio—3.063.063.493.724.995.244.304.211.802.613.313.463.083.033.384.183.72
Debt to equity—0.08——0.130.390.270.240.310.350.190.160.150.120.120.100.070.07
Net debt / EBITDA—−0.68——−0.75−0.58−0.69−0.89−0.55−0.26−0.44−0.68−0.70−0.43−0.32−0.65−2.14−2.48
Interest coverage23.83111.37112.7591.3988.1452.6967.1437.1939.1346.9625.0255.4056.8191.8678.0474.3769.6361.97
Cash conversion79.6%44.2%87.0%97.8%86.8%93.5%116%90.3%92.8%143%95.3%88.7%78.6%93.6%64.0%45.8%6.9%124%
SBC / Revenue2.3%2.1%2.0%2.1%2.2%2.3%2.1%2.0%1.9%1.8%1.9%1.9%2.1%2.1%2.8%2.8%3.0%2.6%

Quarterly

Edwards Lifesciences Corp ratios, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Gross margin80.2%78.4%79.9%80.6%78.9%78.7%77.5%77.8%78.1%78.0%77.5%78.5%
Operating margin45.2%26.2%26.8%25.9%22.6%27.9%26.8%19.8%9.6%29.0%29.5%17.4%
Net margin29.2%26.5%26.7%227%27.8%25.3%21.7%18.7%5.8%23.1%13.9%17.9%
Free cash flow margin3.8%−8.9%20.9%22.1%−12.8%15.9%15.7%33.2%22.5%−1.3%33.6%29.5%
Return on equity5.6%4.9%4.9%32.2%3.9%3.5%3.2%2.9%0.9%3.7%2.3%2.8%
Return on assets5.3%3.1%3.4%2.4%2.1%2.5%2.6%1.9%0.8%3.0%1.7%1.8%
Return on capital employed7.0%4.0%4.1%3.2%2.7%3.4%3.4%2.6%1.3%4.0%4.2%2.4%
Return on invested capital7.5%4.4%5.0%4.8%3.6%4.3%4.3%3.3%1.4%4.8%2.9%3.1%
Current ratio3.383.753.713.464.184.454.684.003.724.424.524.60
Debt to equity0.100.100.090.070.070.070.070.070.070.070.070.06
Net debt / EBITDA−1.56−2.58−3.19−9.71−9.22−7.42−7.48−9.07−18.17−5.73−6.38−11.45
Cash conversion13.1%−33.8%78.1%9.8%−46.0%62.7%72.3%177%388%−5.5%242%165%
SBC / Revenue2.4%3.4%3.2%3.1%2.3%2.8%2.4%2.7%2.5%2.8%2.4%2.7%

The main figures as JSON and plain text. See data and methodology.

EW in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.